- Home
- PHAR vs VTS Comparison
PHAR vs VTS Comparison
Compare PHAR & VTS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PHAR
- VTS
- Stock Information
- Founded
- PHAR 1988
- VTS 2014
- Country
- PHAR Netherlands
- VTS United States
- Employees
- PHAR N/A
- VTS N/A
- Industry
- PHAR Biotechnology: Pharmaceutical Preparations
- VTS Oil & Gas Production
- Sector
- PHAR Health Care
- VTS Energy
- Exchange
- PHAR Nasdaq
- VTS Nasdaq
- Market Cap
- PHAR 951.7M
- VTS 817.2M
- IPO Year
- PHAR N/A
- VTS N/A
- Fundamental
- Price
- PHAR $17.07
- VTS $20.84
- Analyst Decision
- PHAR Strong Buy
- VTS Strong Buy
- Analyst Count
- PHAR 3
- VTS 4
- Target Price
- PHAR $30.00
- VTS $28.25
- AVG Volume (30 Days)
- PHAR 19.8K
- VTS 380.9K
- Earning Date
- PHAR 11-06-2025
- VTS 11-03-2025
- Dividend Yield
- PHAR N/A
- VTS 10.81%
- EPS Growth
- PHAR N/A
- VTS N/A
- EPS
- PHAR 0.00
- VTS 0.56
- Revenue
- PHAR $362,274,000.00
- VTS $248,169,000.00
- Revenue This Year
- PHAR $17.70
- VTS $28.41
- Revenue Next Year
- PHAR $12.25
- VTS N/A
- P/E Ratio
- PHAR $3,068.84
- VTS $37.34
- Revenue Growth
- PHAR 26.78
- VTS 6.73
- 52 Week Low
- PHAR $7.35
- VTS $18.90
- 52 Week High
- PHAR $17.76
- VTS $28.41
- Technical
- Relative Strength Index (RSI)
- PHAR 60.37
- VTS 41.64
- Support Level
- PHAR $15.81
- VTS $20.24
- Resistance Level
- PHAR $17.50
- VTS $21.03
- Average True Range (ATR)
- PHAR 0.91
- VTS 0.64
- MACD
- PHAR 0.09
- VTS 0.05
- Stochastic Oscillator
- PHAR 80.47
- VTS 35.06
About PHAR Pharming Group N.V.
Pharming Group is a biopharmaceutical company focused in transforming the lives of patients with rare, debilitating, and life-threatening diseases. The company is actively developing and commercializing a diverse portfolio of innovative treatments, including both biologics and small molecule therapies. Its commercial products are RUCONEST, approved for the treatment of acute attacks in adult and adolescent patients with hereditary angioedema, or HAE; and Joenja (leniolisib), a small-molecule kinase inhibitor, developed for the treatment of activated phosphoinositide 3-kinase delta syndrome.
About VTS Vitesse Energy Inc.
Vitesse Energy Inc is an independent energy company focused on returning capital to stockholders through owning interests as a non-operator in oil and natural gas wells. It is engaged in the acquisition, development, and production of non-operated oil and natural gas properties in the United States that are generally operated by oil companies and are in the Williston Basin of North Dakota and Montana. The company also have properties in the Central Rockies, including the Denver-Julesburg Basin and the Powder River Basin.